Deleterious AHNAK2 Mutation as a Novel Biomarker for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
doi: 10.3389/fonc.2022.798401. eCollection 2022. Affiliations Expand Affiliations 1 Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. 2 Department of Pathology, The First Affiliated Hospital of […]